P-281JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1 antibody) maintenance therapy vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer

ABSTRACT:

SUBMITTER: Julien T 

PROVIDER: S-EPMC4984068 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature